DMK PHARMACEUTICALS CORPORATION Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2021-09-01: Study NCT04729595; Company role Lead sponsor; Phase Phase 2, Phase 3; Status Terminated.
- 2019-02: Study NCT03835871; Company role Lead sponsor; Phase Phase 3; Status Withdrawn.
- 2019-02: Study NCT03834012; Company role Lead sponsor; Phase Phase 3; Status Withdrawn.
- 2011-08: Study NCT01436214; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Unknown.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2021-09-01 | NCT04729595 Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients. | Lead sponsor | Phase 2, Phase 3 | Terminated | Covid19 | 248 | 2022-09-21 |
| 2019-02 | NCT03835871 Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma | Lead sponsor | Phase 3 | Withdrawn | Asthma | 0 | 2020-05 |
| 2019-02 | NCT03834012 Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma | Lead sponsor | Phase 3 | Withdrawn | Asthma | 0 | 2020-04 |
| 2011-08 | NCT01436214 Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer | Lead sponsor | Phase 1, Phase 2 | Unknown | Prostate Cancer | 60 | 2017-08 |